Alaxo Airway Stents (Alaxo) is pleased to announce that Mark Collins has joined Alaxo as a Spokesperson and Ambassador, effective June 1, 2020.
“We are excited to welcome Mark as Alaxo’s new Spokesperson and Ambassador,” said Terry Bayliss, CEO of Alaxo. “As Alaxo starts exploring the athletic market for our airway stents, Mark brings a wealth of knowledge and elite sport experience, having excelled at the highest level of football and by playing in three Super Bowls.”
“We are excited to welcome Brian as Alaxo’s new Spokesperson and Ambassador,” said Terry Bayliss, CEO of Alaxo. “As we start exploring the athletic and sport potential of our airway stents, Brian brings to the company a wealth of knowledge and professional sports experience, having played in the National Hockey League for 10 years.”
Alaxo Airway Stents (Alaxo), providers of FDA-cleared and Health Canada registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions for snoring, sleep apnea and enhanced athletic performance, announces its collaborative partnership with the Healthy Trucking Association of America (HTAA). Alaxo stents are expected to deliver better health and more restful sleep to HTAA independent owner/operators and fleet drivers, representing seven million highly insured professional drivers.
Terry Bayliss, CEO, Alaxo, says, “We are excited to welcome Nick to our Alaxo team. As we expand our footprint into the sports world, Nick brings a diverse background in the golf world as a former PGA Tour Player and current Player Agent. We are looking forward to working with Nick and exploring the opportunities Nick brings in the golf world as well as the medical community.”
Alaxo Airway Stents (Alaxo), providers of FDA and Health Canada registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions for snoring, sleep apnea and enhanced athletic performance, has selected CPR Strategic Marketing Communications (CPR) to accelerate corporate growth, provider prescribing and patient adoption of Alaxo’s four stent products which can potentially replace existing snoring devices, as well as CPAP machines used to treat snoring and sleep apnea. Alaxo stents have been identified as a potential treatment for coronavirus-based viruses due to increased production of inhaled nitric oxide as an evidence-based, effective therapeutic for imminent and manifested respiratory insufficiency conditions.
Terry Bayliss, CEO, Alaxo, says, “The CPR team has the expertise and track record for designing and implementing compelling, credible marketing communications campaigns for leading healthcare companies worldwide, and we will rely upon its guidance to gain significant market traction for Alaxo.”
“We are pleased to partner with Singular,” said Terry Bayliss, CEO of Alaxo. “As people continue to adapt to the struggles created by the CoVID-19 pandemic, those healthcare providers who use telemedicine realize this is the way of future health delivery. Our partnership with Singular lends to our combined ability to provide a complete sleep solution for our customers throughout the United States.”
Dr Krainin states, “We are enthusiastic about this collaboration with Alaxo to offer a new “alternative to CPAP” treatment. I am constantly looking for new, FDA-approved treatments for my patients who have failed CPAP and the Alaxo Airway Stents are an exciting new treatment modality.”
About Singular Sleep
Singular Sleep is the first-ever completely online sleep center. Founded in 2015 by board-certified sleep doctor Dr. Joseph Krainin, the company specializes in the remote diagnosis and treatment of sleep apnea.